-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Sanofi China announced that two of the company's drugs in the field of cardiovascular diseases, the original clopidogrel (Polivi®) and the original irbesartan hydrochlorothiazide (Ambonol®), have been successfully included in the Guangdong Alliance's procurement list
The inter-provincial drug procurement alliance led by Guangdong Province covers Guangdong, Shanxi, Henan, Hunan, Guangxi, Xinjiang and other provinces, and is currently one of the largest local centralized procurement alliances
Professor Dong Yugang, director of the Department of Cardiovascular Medicine of the First Affiliated Hospital of Sun Yat-sen University, pointed out: “The centralized procurement of medicines has brought tangible benefits to the masses, and patients can afford and buy high-quality drugs
Clopidogrel is used for the treatment of myocardial infarction, ischemic stroke, peripheral arterial disease and acute coronary syndrome (ACS); irbesartan and hydrochlorothiazide are used for the treatment of essential hypertension
Liu Jing, general manager of Sanofi's China Innovation and Core Business Department, said: "Deeply cultivating the Chinese market for nearly 40 years, Sanofi has always adhered to the patient-centered concept and escorted the health of the Chinese people with high-quality drugs and services
At present, cardiovascular disease has become a major type of disease that seriously threatens the health of Chinese residents, and is a major health problem that affects the country's economic and social development
Reference: National Center for Cardiovascular Diseases.